Computational Evaluation of Miconazole and Its Proposed Cu(II) and Co(II) Complexes against PBP2a: Molecular Docking and ADME Predictions
Methicillin-resistant Staphylococcus aureus (MRSA) remains a major clinical problem because the mecA-encoded penicillin-binding protein 2a (PBP2a) sustains cell-wall synthesis in the presence of β-lactams. Miconazole, an imidazole antifungal, has reported in vitro activity against MRSA, and coordination of azoles to transition metals has been associated with enhanced antimicrobial activity. In this in silico study, free miconazole and its hypothetical Cu(II) and Co(II) complexes were docked against PBP2a (PDB ID: 1VQQ) and the docking was repeated to assess reproducibility. Initial docking scores were −7.2 (free miconazole), −7.4 (Cu complex) and −7.2 kcal/mol (Co complex); repeated docking gave −7.1, −6.9 and −7.0 kcal/mol, respectively, i.e. fluctuations of ≤ 0.5 kcal/mol, with an RMSD of 1.397 Å between runs for the Cu system. SwissADME predicted high gastrointestinal absorption for all three compounds, a decrease in TPSA from 27.05 to 15.71 Ų upon metal coordination, and no P-glycoprotein substrate behaviour. These values are computational predictions only: SwissADME is parameterised for organic molecules, so the descriptors of the metal complexes should be treated as indicative, and the docking scores are not experimental evidence of PBP2a inhibition. The results justify, but do not replace, synthesis and antibacterial testing of the complexes.
Authors
- iman jaaffer
Institutions
- University of Basrah (IQ)
Publication Details
- Journal
- Advanced Journal of Scientific Research
- Published
- 2026-11-15
- DOI
- https://doi.org/10.67364/hy069055
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00